Cathie Wood's ARK Invest expanded its position in Rocket Lab (RKLB) by approximately $25 million on Tuesday while simultaneously reducing its stake in technology giant Alphabet (GOOGL).

The purchase involved 359,612 Rocket Lab shares distributed across three of the firm's funds: ARKK, the ARK Innovation ETF; ARKQ, the Autonomous Technology and Robotics ETF; and ARKX, its space exploration ETF. The acquisitions totaled approximately $25.1 million and extend a position ARK has steadily built as the stock experienced recent downward pressure.

After the transaction, ARK's total ownership reportedly stands at more than 3.2 million Rocket Lab shares across its ETF lineup, a combined market value approaching $225 million at current prices.

ARK Invest manages a suite of actively traded thematic ETFs and publishes its daily portfolio transactions. Its funds target what the firm describes as disruptive innovation, spanning genomics, artificial intelligence, fintech, aerospace, and robotics. Because those disclosures arrive every trading day, the firm's buys and sells are closely followed by investors looking for a same-day window into how a prominent thematic manager is positioning across emerging industries.

Continued Accumulation of Rocket Lab Shares

Rocket Lab USA, Inc. (Nasdaq: RKLB) built its reputation on Electron, its dedicated launch vehicle for small satellites, though the company's longer-term investment appeal centers heavily on Neutron, a next-generation reusable launch system designed to capture market share in the medium-lift segment.

The company has set a target launch window for the fourth quarter of 2026, though management has acknowledged that qualification testing timelines could potentially push the inaugural flight into 2027. That testing campaign therefore gives observers a concrete company-specific checkpoint, since Neutron's progress underpins much of the growth thesis attached to the stock.

Beyond launch operations, Rocket Lab continues to diversify into satellite manufacturing and communications technologies, an expansion that positions the company to capitalize on multiple segments of the growing commercial and defense space sectors.

ARK's latest acquisition follows a pattern of consistent buying during Rocket Lab's decline from the peak valuations reached in May. That sustained accumulation indicates the firm remains committed to the position as the shares show signs of recovery — and because the firm discloses its trades daily, any continuation or pause in the buying will surface in its regular updates.

Alphabet Position Reduction

Concurrently, ARK liquidated 16,422 shares of Alphabet Inc. (Nasdaq: GOOGL) distributed between ARKQ and ARKX, generating proceeds of approximately $5.8 million — a modest transaction relative to the Rocket Lab purchase.

Alphabet maintains its status among the world's dominant and highly profitable technology enterprises, but market participants continue to analyze how artificial intelligence development might affect its core search revenue. That ongoing debate is the backdrop against which ARK's trim, however small, will be read by followers of the firm's daily moves.

Google has been aggressively expanding its Gemini AI platform and developing proprietary AI processors, providing Alphabet with enhanced participation in both AI infrastructure and software ecosystems.

The transaction also highlights the differing profiles of the two holdings. Alphabet generates substantial cash flows from its established businesses, whereas Rocket Lab's valuation rests largely on projected growth from its launch operations, Neutron deployment, and broader space infrastructure ambitions.

Biotechnology Portfolio Adjustments

ARK also executed a series of biotechnology transactions on Tuesday, adding to its exposure in the sector. The firm acquired 88,323 shares of Scribe Therapeutics valued at approximately $2.5 million, complemented by smaller acquisitions in Veracyte and Beam Therapeutics.

On the sales side, ARK trimmed its holdings in both Twist Bioscience and 10X Genomics, and sold 19,139 shares of Everpure through the ARKW fund.

The Rocket Lab transaction clearly dominated Tuesday's trading activity, underscoring ARK's ongoing commitment to disruptive innovation themes spanning aerospace, biotechnology, and next-generation technology sectors.

Source: Blockonomi